UnknownPhase 2NCT03772132

Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Studying Carcinoma of gallbladder and extrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Jiao Tong University School of Medicine
Principal Investigator
yingbin liu, PHD, M.D., Ph.D
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Intervention
mutation and signal pathway activation status analysis Drug: FORFIRINOX(biological)
Enrollment
100 enrolled
Eligibility
18-80 years · All sexes
Timeline
20162021

Study locations (1)

Collaborators

Ruijin Hospital · RenJi Hospital · Eastern Hepatobiliary Surgery Hospital · Huashan Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03772132 on ClinicalTrials.gov

Other trials for Carcinoma of gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Carcinoma of gallbladder and extrahepatic biliary tract

← Back to all trials